{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:26:58Z","timestamp":1778858818187,"version":"3.51.4"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32DK007191-48"],"award-info":[{"award-number":["5T32DK007191-48"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Infection with chronic hepatitis C virus (HCV) is an important risk factor for hepatocellular carcinoma (HCC). Direct-acting antiviral therapy has transformed care for patients with HCV and reduces the risk of HCC. Despite HCV cure, a residual HCC risk remains in patients with advanced fibrosis and cirrhosis, with multiple mechanisms underlying subsequent hepatocarcinogenesis. Transcriptomic and proteomic signatures demonstrate the capacity for HCC risk stratification, and chemoprevention strategies are emerging. For now, pending more precise stratification, HCC surveillance of patients with cured HCV and advanced fibrosis or cirrhosis should continue.<\/jats:p>","DOI":"10.1093\/infdis\/jiac447","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:00:45Z","timestamp":1694624445000},"page":"S226-S231","source":"Crossref","is-referenced-by-count":3,"title":["Unmet Needs in the Post\u2013Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication"],"prefix":"10.1093","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5664-3361","authenticated-orcid":false,"given":"Eric M","family":"Przybyszewski","sequence":"first","affiliation":[{"name":"Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T","family":"Chung","sequence":"additional","affiliation":[{"name":"Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"2023091317000487500_jiac447-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023091317000487500_jiac447-B2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023091317000487500_jiac447-B3","author":"World Health Organization","year":"2021"},{"key":"2023091317000487500_jiac447-B4","author":"Word Health Organization","year":"2016"},{"key":"2023091317000487500_jiac447-B5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B7","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular carcinoma in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B11","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B14","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"2023091317000487500_jiac447-B15","first-page":"1683","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2015","journal-title":"JAMA Oncology"},{"key":"2023091317000487500_jiac447-B16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jhep.2010.01.033","article-title":"Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study","volume":"53","author":"Omland","year":"2010","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","article-title":"The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of Veterans Affairs clinical registry","volume":"172","author":"McCombs","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2023091317000487500_jiac447-B19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving sustained virologic response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023091317000487500_jiac447-B20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B21","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","article-title":"Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population","volume":"312","author":"van der Meer","year":"2014","journal-title":"JAMA"},{"key":"2023091317000487500_jiac447-B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cgh.2009.10.026","article-title":"Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023091317000487500_jiac447-B23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"2023091317000487500_jiac447-B24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep.30303","article-title":"Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States","volume":"69","author":"Park","year":"2019","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV reduces viral hepatitis-associated liver-related morality in patients: an ERCHIVES study","volume":"73","author":"Butt","year":"2020","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2021.05.028","article-title":"Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study","volume":"75","author":"Janjua","year":"2021","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B28","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","article-title":"Management of the patient with SVR","volume":"65","author":"Terrault","year":"2016","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.patbio.2009.11.001","article-title":"Pathogenesis of hepatitis B virus infection","volume":"58","author":"Chisari","year":"2010","journal-title":"Pathol Biol (Paris)"},{"key":"2023091317000487500_jiac447-B31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"2023091317000487500_jiac447-B32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1053\/j.gastro.2004.07.009","article-title":"Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma","volume":"127","author":"Merle","year":"2004","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/hep.20668","article-title":"Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression","volume":"41","author":"Fukutomi","year":"2005","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"2023091317000487500_jiac447-B35","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1099\/vir.0.000145","article-title":"Hepatitis C virus NS5A protein blocks epidermal growth factor receptor degradation via a proline motif-dependent interaction","volume":"96","author":"Igloi","year":"2015","journal-title":"J Gen Virol"},{"key":"2023091317000487500_jiac447-B36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.gastro.2011.03.045","article-title":"A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma","volume":"141","author":"Abu Dayyeh","year":"2011","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B37","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1002\/hep4.1991","article-title":"Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature","volume":"6","author":"Kim","year":"2022","journal-title":"Hepatol Commun"},{"key":"2023091317000487500_jiac447-B38","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B39","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.31462","article-title":"Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease","volume":"73","author":"Semmler","year":"2021","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"2023091317000487500_jiac447-B41","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Hoshida","year":"2008","journal-title":"N Eng J Med"},{"key":"2023091317000487500_jiac447-B42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2013.01.021","article-title":"Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis","volume":"144","author":"Hoshida","year":"2013","journal-title":"Gastroenterology"},{"key":"2023091317000487500_jiac447-B43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/gutjnl-2014-307862","article-title":"A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration","volume":"64","author":"King","year":"2015","journal-title":"Gut"},{"key":"2023091317000487500_jiac447-B44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition","volume":"30","author":"Nakagawa","year":"2016","journal-title":"Cancer Cell"},{"key":"2023091317000487500_jiac447-B45","doi-asserted-by":"crossref","first-page":"15350","DOI":"10.18632\/oncotarget.24601","article-title":"Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma","volume":"9","author":"Moshiri","year":"2018","journal-title":"Oncotarget"},{"key":"2023091317000487500_jiac447-B46","first-page":"836","article-title":"A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced fibrosis","volume":"2","author":"Fujiwara","year":"2021","journal-title":"Med (N Y)"},{"key":"2023091317000487500_jiac447-B47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15626","article-title":"Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis","volume":"3","author":"Ioannou","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2023091317000487500_jiac447-B48","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.31500","article-title":"Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs","volume":"72","author":"Degasperi","year":"2020","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.14309\/ajg.0000000000001897","article-title":"Moving away from a one-size-fits-all approach to hepatocellular carcinoma surveillance","volume":"117","author":"Moon","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2023091317000487500_jiac447-B50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CEJ.0000000000000252","article-title":"Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies","volume":"26","author":"Bravi","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"2023091317000487500_jiac447-B51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jnci\/djz122","article-title":"Prospective investigation of serum metabolites, coffee drinking, liver cancer incidence, and liver disease mortality","volume":"112","author":"Loftfield","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2023091317000487500_jiac447-B52","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N Eng J Med"},{"key":"2023091317000487500_jiac447-B53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7326\/M18-2753","article-title":"Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population","volume":"171","author":"Simon","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023091317000487500_jiac447-B54","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes mediations and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"Kramer","year":"2022","journal-title":"Hepatology"},{"key":"2023091317000487500_jiac447-B55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_3\/S226\/51544034\/jiac447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_3\/S226\/51544034\/jiac447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:01:02Z","timestamp":1694624462000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_3\/S226\/7273013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":55,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2023,9,13]]},"published-print":{"date-parts":[[2023,9,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac447","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,9,13]]}}}